Aurobindo Pharma (India) Top Management

AUROPHARMA   1,224  6.70  0.55%   
Aurobindo Pharma employs about 26 K people. The company is managed by 21 executives with a total tenure of roughly 60702 years, averaging almost 2890.0 years of service per executive, having 1238.81 employees per reported executive. Analysis of Aurobindo Pharma's management performance can provide insight into the company performance.
BE MBA  CEO
CEO Biologics
Puvvala Yugandhar  CEO
CEO Specialities
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurobindo Pharma Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Aurobindo Pharma Management Team Effectiveness

The company has return on total asset (ROA) of 0.0677 % which means that it generated a profit of $0.0677 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1213 %, meaning that it generated $0.1213 on every $100 dollars invested by stockholders. Aurobindo Pharma's management efficiency ratios could be used to measure how well Aurobindo Pharma manages its routine affairs as well as how well it operates its assets and liabilities. At present, Aurobindo Pharma's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 219.1 B, whereas Non Currrent Assets Other are forecasted to decline to about 3.8 B.
The current year's Net Income Applicable To Common Shares is expected to grow to about 27.1 B, whereas Common Stock Shares Outstanding is forecasted to decline to about 649.9 M.

Aurobindo Pharma Workforce Comparison

Aurobindo Pharma Limited is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 40,139. Aurobindo Pharma totals roughly 26,015 in number of employees claiming about 65% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.12 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.15 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.15.

Aurobindo Pharma Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Aurobindo Pharma Price Series Summation is a cross summation of Aurobindo Pharma price series and its benchmark/peer.

Aurobindo Pharma Notable Stakeholders

An Aurobindo Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aurobindo Pharma often face trade-offs trying to please all of them. Aurobindo Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aurobindo Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
BE MBACEO BiologicsProfile
Puvvala YugandharCEO SpecialitiesProfile
Rama RaoPresident QAProfile
Venugopalan MuralidharanPresident BusinessProfile
Vijaya KumarPresident TechnicalProfile
V HandaPresident ResearchProfile
Sanjeev DaniCOO FormulationsProfile
Penaka ReddyWholeTime DirectorProfile
Meenakshi SivakumaranWholeTime DirectorProfile
Mettu ReddyWholeTime DirectorProfile
RavikiranChief OfficerProfile
G PrasadSenior OperationsProfile
Sanjay MScChief LimitedProfile
DamodharanChief verticalProfile
Kambam ReddyVice MDProfile
Swami IyerChief AmericaProfile
Sudhir SinghiHead OperationsProfile
Arvind BothraHead CommunicationsProfile
Shriniwas DangeInvestor ExecutiveProfile
Adi ReddyCompliance SecretaryProfile
Santhanam SubramanianChief OfficerProfile

About Aurobindo Pharma Management Performance

The success or failure of an entity such as Aurobindo Pharma often depends on how effective the management is. Aurobindo Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aurobindo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aurobindo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Aurobindo Pharma is entity of India. It is traded as Stock on NSE exchange.
Please note, the presentation of Aurobindo Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aurobindo Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Aurobindo Pharma's management manipulating its earnings.

Aurobindo Pharma Workforce Analysis

Traditionally, organizations such as Aurobindo Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aurobindo Pharma within its industry.

Aurobindo Pharma Manpower Efficiency

Return on Aurobindo Pharma Manpower

Revenue Per Employee11.1M
Revenue Per Executive13.8B
Net Income Per Employee1.2M
Net Income Per Executive1.5B
Working Capital Per Employee4.6M
Working Capital Per Executive5.7B

Complementary Tools for Aurobindo Stock analysis

When running Aurobindo Pharma's price analysis, check to measure Aurobindo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurobindo Pharma is operating at the current time. Most of Aurobindo Pharma's value examination focuses on studying past and present price action to predict the probability of Aurobindo Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurobindo Pharma's price. Additionally, you may evaluate how the addition of Aurobindo Pharma to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Commodity Directory
Find actively traded commodities issued by global exchanges